Turn Therapeutics (TTRX) closed at $8.55 on November 16, 2026, down 8.5% from the previous close, on volume of 147,782 shares (30-day average 95,112).
Data as of November 16, 2026.
16-Nov-2026
No headlines found.
Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London
Business Wire (Mon, 16-Nov 7:00 AM ET)
Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
Business Wire (Mon, 9-Nov 7:00 AM ET)
Business Wire (Thu, 5-Nov 8:00 AM ET)
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
Business Wire (Wed, 21-Oct 4:01 PM ET)
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Business Wire (Thu, 10-Sep 8:00 AM ET)
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
Business Wire (Wed, 9-Sep 8:00 AM ET)
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
Globe Newswire (Tue, 8-Sep 7:00 AM ET)
Business Wire (Thu, 20-Aug 8:00 AM ET)
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Turn Therapeutics trades on the NASDAQ stock market under the symbol TTRX.
As of November 16, 2026, TTRX stock price declined to $8.55 with 147,782 million shares trading.
TTRX has a beta of 0.83, meaning it tends to be less sensitive to market movements. TTRX has a correlation of 0.01 to the broad based SPY ETF.
TTRX has a market cap of $261.40 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that TTRX belongs to (by Net Assets): VTI, VXF, IWC, BUSM.
TTRX has outperformed the market in the last year with a return of +109.0%, while the SPY ETF gained +11.2%. However, in the most recent history, TTRX shares have underperformed the stock market with its stock returning -13.3% in the last 3 month period and -18.0% for the last 2 week period, while SPY has returned -4.6% and -2.1%, respectively.
TTRX support price is $8.69 and resistance is $10.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TTRX shares will trade within this expected range on the day.